// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review

April Jorge - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Hydroxychloroquine

The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease

Hayley Epstein - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy

Xavier M Teitsma - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis

Jessie Alperin - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review

Caroline H. Siegel - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Hydroxychloroquine-Mediated Cardiotoxicity with a False Positive 99M-Technetium Labeled Pyrophosphate Scan for Amyloidosis

Ian C. Chang - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Hydroxychloroquine

Reversal of cardiac remodelling after treatment of IgG4 related cholangitis

Z.H. Wei - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Hydroxychloroquine

Photodistributed Granuloma Annulare

Katie Benjegerdes - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Multiple eruptive verrucous dermatofibromas in the setting of lupus erythematosus and epidermal nevus

Albert Antonyan - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Hydroxychloroquine

Lupus erythematosus panniculitis treated with stromal vascular fraction

Tulin Ergun - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Resolution of Cutaneous Lesions in a Patient with Systemic Lupus Erythematous on Belimumab

Michael Garone - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

" A sword that cuts deeper than the skin"

Preeti Jhorar - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Hydroxychloroquine

Dermatomyositis-Associated Panniculitis

Jenna Beasley - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Bullous Dermatomyositis: a rare sign of underlying malignancy and poor prognosis

Jose E. Ollague - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Bullous systemic lupus erythematosus presenting initially as a vesicobullous eruption without overt manifestations of SLE

Elisa Rae Coo - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Hydralazine-induced bullous flare of systemic lupus erythematosus

Elizabeth Schepp - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Porphyria cutanae tarda presenting with scleromatous changes and scarring alopecia

Evelyn Alarcon Chinchilla - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Hydroxychloroquine

Verrucous carcinoma arising within hypertrophic lichen planus

Thy Huynh - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

Hydroxychloroquine

Atypical Variants of Morphea on the Face: Report of Three Cases

Rawaa Almukhtar - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Hydroxychloroquine

A case of mixed cryoglobulinaemic vasculitis and autoimmune hepatitis successfully treated with Rituximab

Antonia Lloyd-Lavery - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved